<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39444885</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">2072-1439</ISSN><JournalIssue CitedMedium="Print"><Volume>16</Volume><Issue>9</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>30</Day></PubDate></JournalIssue><Title>Journal of thoracic disease</Title><ISOAbbreviation>J Thorac Dis</ISOAbbreviation></Journal><ArticleTitle>Sivelestat protects against acute lung injury by up-regulating angiotensin-converting enzyme 2/angiotensin-(1-7)/Mas receptors.</ArticleTitle><Pagination><StartPage>6182</StartPage><EndPage>6195</EndPage><MedlinePgn>6182-6195</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.21037/jtd-24-1281</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">Acute lung injury (ALI) and its most severe manifestation of acute respiratory distress syndrome (ARDS) is a disease with a clinical mortality rate of up to 40% and is one of the most dangerous and common complications of severe coronavirus disease 2019 (COVID-19). Sivelestat (SIV) is the only licensed therapeutic medicine in the world for ALI/ARDS treatment. The angiotensin-converting enzyme 2 (ACE2)/angiotensin (Ang)-(1-7)/Mas receptor axis is critical in the prevention of ALI/ARDS. This study aims to investigate whether SIV alleviates lipopolysaccharides (LPS)-induced ALI by inhibiting the down-regulation of ACE2/Ang-(1-7)/Mas receptor axis expression.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED"><i>In vivo</i>, 90 male Sprague-Dawley rats were randomized into 5 groups. Then, we pretreated different groups of rats with dexamethasone (DEX) or SIV. Rats were sacrificed at three different time points (3, 6, and 12 hours) following LPS instillation. In vitro, RAW264.7 cells were divided into 11 groups. Different groups of cells were pretreated with DEX or SIV. And then added with LPS for 3, 6, and 12 hours. Next, we introduced A779, a potent Ang-(1-7) receptor antagonist, and DX600 as the ACE2 antagonist in different groups. Then the protein and messenger RNA (mRNA) expression levels of ACE2 in rat lung tissue and the expression levels of tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6) and Ang-(1-7) in the rat serum and the cell culture supernatant were measured. And the data were statistically analyzed.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED"><i>In vivo</i>, the rats pretreated with SIV or DEX had significantly lower lung wet/dry (W/D) ratios and lung pathological alterations than those exposed to LPS only. Both <i>in vivo</i> and <i>in vitro</i>, we observed that SIV or DEX significantly attenuated the LPS-induced up-regulation of IL-6 and TNF-α levels, and the down-regulation of ACE2 and Ang-(1-7) levels. <i>In vitro</i>, the pretreatment of the RAW264.7 cells with DX600 and A779 significantly reduced and even abolished the protective effects of SIV.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">Therefore, it was concluded that SIV protected against LPS-induced ALI and decreased inflammatory cytokine release by up-regulating the ACE2/Ang-(1-7)/Mas receptor axis. Our results enrich the theoretical foundation for the clinical application of SIV and provide fresh ideas for the treatment of ALI/ARDS.</AbstractText><CopyrightInformation>2024 AME Publishing Company. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>He</LastName><ForeName>Changqing</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Respiratory Medicine, First Affiliated Hospital of Jinzhou Medical University, Jinzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Ruoxin</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Respiratory Medicine, First Affiliated Hospital of Jinzhou Medical University, Jinzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Jia</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Respiratory Medicine, First Affiliated Hospital of Jinzhou Medical University, Jinzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chai</LastName><ForeName>Wenshu</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Respiratory Medicine, First Affiliated Hospital of Jinzhou Medical University, Jinzhou, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>China</Country><MedlineTA>J Thorac Dis</MedlineTA><NlmUniqueID>101533916</NlmUniqueID><ISSNLinking>2072-1439</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Sivelestat (SIV)</Keyword><Keyword MajorTopicYN="N">acute lung injury (ALI)</Keyword><Keyword MajorTopicYN="N">angiotensin-(1–7) [Ang-(1–7)]</Keyword><Keyword MajorTopicYN="N">angiotensin-converting enzyme 2 (ACE2)</Keyword><Keyword MajorTopicYN="N">lipopolysaccharide (LPS)</Keyword></KeywordList><CoiStatement>Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://jtd.amegroups.com/article/view/10.21037/jtd-24-1281/coif). The authors have no conflicts of interest to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>24</Day><Hour>16</Hour><Minute>51</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>24</Day><Hour>16</Hour><Minute>50</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>24</Day><Hour>4</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>30</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39444885</ArticleId><ArticleId IdType="pmc">PMC11494560</ArticleId><ArticleId IdType="doi">10.21037/jtd-24-1281</ArticleId><ArticleId IdType="pii">jtd-16-09-6182</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Gorman EA, O'Kane CM, McAuley DF. Acute respiratory distress syndrome in adults: diagnosis, outcomes, long-term sequelae, and management. Lancet 2022;400:1157-70. 10.1016/S0140-6736(22)01439-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)01439-8</ArticleId><ArticleId IdType="pubmed">36070788</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaku S, Nguyen CD, Htet NN, et al. Acute Respiratory Distress Syndrome: Etiology, Pathogenesis, and Summary on Management. J Intensive Care Med 2020;35:723-37. 10.1177/0885066619855021</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0885066619855021</ArticleId><ArticleId IdType="pubmed">31208266</ArticleId></ArticleIdList></Reference><Reference><Citation>Li L, Huang Q, Wang DC, et al. Acute lung injury in patients with COVID-19 infection. Clin Transl Med 2020;10:20-7. 10.1002/ctm2.16</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ctm2.16</ArticleId><ArticleId IdType="pmc">PMC7240840</ArticleId><ArticleId IdType="pubmed">32508022</ArticleId></ArticleIdList></Reference><Reference><Citation>Millar MW, Fazal F, Rahman A. Therapeutic Targeting of NF-κB in Acute Lung Injury: A Double-Edged Sword. Cells 2022;11:3317. 10.3390/cells11203317</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells11203317</ArticleId><ArticleId IdType="pmc">PMC9601210</ArticleId><ArticleId IdType="pubmed">36291185</ArticleId></ArticleIdList></Reference><Reference><Citation>Barbeta E, Motos A, Torres A, et al. SARS-CoV-2-induced Acute Respiratory Distress Syndrome: Pulmonary Mechanics and Gas-Exchange Abnormalities. Ann Am Thorac Soc 2020;17:1164-8. 10.1513/AnnalsATS.202005-462RL</Citation><ArticleIdList><ArticleId IdType="doi">10.1513/AnnalsATS.202005-462RL</ArticleId><ArticleId IdType="pmc">PMC7462332</ArticleId><ArticleId IdType="pubmed">32579033</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng HP, Bao XW, Luo YY, et al. Sulfasalazine ameliorates lipopolysaccharide-induced acute lung injury by inhibiting oxidative stress and nuclear factor-kappaB pathways. Int J Biochem Cell Biol 2024;169:106530. Erratum in: Int J Biochem Cell Biol 2024;172:106586.10.1016/j.biocel.2024.106530</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biocel.2024.106530</ArticleId><ArticleId IdType="pubmed">38246263</ArticleId></ArticleIdList></Reference><Reference><Citation>Zou K, Wang C, Zhou C, et al. Early growth response 1/Krüppel-like factor 5 pathway inhibitor alleviates lipopolysaccharide-induced lung injury by promoting autophagy. Eur J Pharmacol 2024;964:176294. 10.1016/j.ejphar.2023.176294</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejphar.2023.176294</ArticleId><ArticleId IdType="pubmed">38158112</ArticleId></ArticleIdList></Reference><Reference><Citation>Pang M, Yuan Y, Wang D, et al. Recombinant CC16 protein inhibits the production of pro-inflammatory cytokines via NF-κB and p38 MAPK pathways in LPS-activated RAW264.7 macrophages. Acta Biochim Biophys Sin (Shanghai) 2017;49:435-43. 10.1093/abbs/gmx020</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/abbs/gmx020</ArticleId><ArticleId IdType="pmc">PMC5412021</ArticleId><ArticleId IdType="pubmed">28338974</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdelhamid AM, El Deeb M, Zaafan MA. The protective effect of xanthenone against LPS-induced COVID-19 acute respiratory distress syndrome (ARDS) by modulating the ACE2/Ang-1-7 signaling pathway. Eur Rev Med Pharmacol Sci 2022;26:5285-96. 10.26355/eurrev_202207_29320</Citation><ArticleIdList><ArticleId IdType="doi">10.26355/eurrev_202207_29320</ArticleId><ArticleId IdType="pubmed">35916829</ArticleId></ArticleIdList></Reference><Reference><Citation>Du HL, Zhai AD, Yu H. Synergistic effect of halofuginone and dexamethasone on LPS-induced acute lung injury in type II alveolar epithelial cells and a rat model. Mol Med Rep 2020;21:927-35. 10.3892/mmr.2019.10865</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/mmr.2019.10865</ArticleId><ArticleId IdType="pubmed">31974595</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiu Y, Tang Z. Dexmedetomidine Attenuates LPS-Induced Acute Lung Injury in Rats by Activating the Nrf2/ARE Pathway. J Healthc Eng 2022;2022:4185195. 10.1155/2022/4185195</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2022/4185195</ArticleId><ArticleId IdType="pmc">PMC9017427</ArticleId><ArticleId IdType="pubmed">35449859</ArticleId></ArticleIdList></Reference><Reference><Citation>Bi Z, Hong W, Que H, et al. Inactivated SARS-CoV-2 induces acute respiratory distress syndrome in human ACE2-transgenic mice. Signal Transduct Target Ther 2021;6:439. 10.1038/s41392-021-00851-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-021-00851-6</ArticleId><ArticleId IdType="pmc">PMC8705082</ArticleId><ArticleId IdType="pubmed">34952899</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim MA, Pranata R. Worrying situation regarding the use of dexamethasone for COVID-19. Ther Adv Respir Dis 2020;14:1753466620942131. 10.1177/1753466620942131</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1753466620942131</ArticleId><ArticleId IdType="pmc">PMC7372607</ArticleId><ArticleId IdType="pubmed">32684095</ArticleId></ArticleIdList></Reference><Reference><Citation>Vecchié A, Batticciotto A, Tangianu F, et al. High-dose dexamethasone treatment for COVID-19 severe acute respiratory distress syndrome: a retrospective study. Intern Emerg Med 2021;16:1913-9. 10.1007/s11739-021-02800-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11739-021-02800-1</ArticleId><ArticleId IdType="pmc">PMC8286167</ArticleId><ArticleId IdType="pubmed">34275096</ArticleId></ArticleIdList></Reference><Reference><Citation>Beyerstedt S, Casaro EB, Rangel ÉB. COVID-19: angiotensin-converting enzyme 2 (ACE2) expression and tissue susceptibility to SARS-CoV-2 infection. Eur J Clin Microbiol Infect Dis 2021;40:905-19. 10.1007/s10096-020-04138-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10096-020-04138-6</ArticleId><ArticleId IdType="pmc">PMC7778857</ArticleId><ArticleId IdType="pubmed">33389262</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie JX, Hu J, Cheng J, et al. The function of the ACE2/Ang(1-7)/Mas receptor axis of the renin-angiotensin system in myocardial ischemia reperfusion injury. Eur Rev Med Pharmacol Sci 2022;26:1852-9. 10.26355/eurrev_202203_28330</Citation><ArticleIdList><ArticleId IdType="doi">10.26355/eurrev_202203_28330</ArticleId><ArticleId IdType="pubmed">35363333</ArticleId></ArticleIdList></Reference><Reference><Citation>Bian J, Li Z. Angiotensin-converting enzyme 2 (ACE2): SARS-CoV-2 receptor and RAS modulator. Acta Pharm Sin B 2021;11:1-12. 10.1016/j.apsb.2020.10.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.apsb.2020.10.006</ArticleId><ArticleId IdType="pmc">PMC7553008</ArticleId><ArticleId IdType="pubmed">33072500</ArticleId></ArticleIdList></Reference><Reference><Citation>Datta PK, Liu F, Fischer T, et al. SARS-CoV-2 pandemic and research gaps: Understanding SARS-CoV-2 interaction with the ACE2 receptor and implications for therapy. Theranostics 2020;10:7448-64. 10.7150/thno.48076</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/thno.48076</ArticleId><ArticleId IdType="pmc">PMC7330865</ArticleId><ArticleId IdType="pubmed">32642005</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Y, Yang X, Ju Y, et al. Fraxinol attenuates LPS-induced acute lung injury by equilibrating ACE-Ang II-AT1R and ACE2-Ang (1-7)-Mas and inhibiting NLRP3. Pharm Biol 2022;60:979-89. 10.1080/13880209.2022.2067571</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/13880209.2022.2067571</ArticleId><ArticleId IdType="pmc">PMC9122403</ArticleId><ArticleId IdType="pubmed">35588103</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J, Dong J, Martin M, et al. AMP-activated Protein Kinase Phosphorylation of Angiotensin-Converting Enzyme 2 in Endothelium Mitigates Pulmonary Hypertension. Am J Respir Crit Care Med 2018;198:509-20. 10.1164/rccm.201712-2570OC</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/rccm.201712-2570OC</ArticleId><ArticleId IdType="pmc">PMC6118028</ArticleId><ArticleId IdType="pubmed">29570986</ArticleId></ArticleIdList></Reference><Reference><Citation>Kido T, Muramatsu K, Yatera K, et al. Efficacy of early sivelestat administration on acute lung injury and acute respiratory distress syndrome. Respirology 2017;22:708-13. 10.1111/resp.12969</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/resp.12969</ArticleId><ArticleId IdType="pubmed">27990710</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyoshi S, Hamada H, Ito R, et al. Usefulness of a selective neutrophil elastase inhibitor, sivelestat, in acute lung injury patients with sepsis. Drug Des Devel Ther 2013;7:305-16. 10.2147/DDDT.S42004</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/DDDT.S42004</ArticleId><ArticleId IdType="pmc">PMC3627345</ArticleId><ArticleId IdType="pubmed">23596346</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayakawa M, Katabami K, Wada T, et al. Sivelestat (selective neutrophil elastase inhibitor) improves the mortality rate of sepsis associated with both acute respiratory distress syndrome and disseminated intravascular coagulation patients. Shock 2010;33:14-8. 10.1097/SHK.0b013e3181aa95c4</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SHK.0b013e3181aa95c4</ArticleId><ArticleId IdType="pubmed">19487982</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashimoto S, Sanui M, Egi M, et al. The clinical practice guideline for the management of ARDS in Japan. J Intensive Care 2017;5:50. 10.1186/s40560-017-0222-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40560-017-0222-3</ArticleId><ArticleId IdType="pmc">PMC5526253</ArticleId><ArticleId IdType="pubmed">28770093</ArticleId></ArticleIdList></Reference><Reference><Citation>Sahebnasagh A, Saghafi F, Safdari M, et al. Neutrophil elastase inhibitor (sivelestat) may be a promising therapeutic option for management of acute lung injury/acute respiratory distress syndrome or disseminated intravascular coagulation in COVID-19. J Clin Pharm Ther 2020;45:1515-9. 10.1111/jcpt.13251</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jcpt.13251</ArticleId><ArticleId IdType="pubmed">32860252</ArticleId></ArticleIdList></Reference><Reference><Citation>Ren J, Deng G, Li R, et al. Possible pharmacological targets and mechanisms of sivelestat in protecting acute lung injury. Comput Biol Med 2024;170:108080. 10.1016/j.compbiomed.2024.108080</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.compbiomed.2024.108080</ArticleId><ArticleId IdType="pubmed">38306776</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan H, Huang W, Wang Z, et al. The ACE2-Ang-(1-7)-Mas Axis Modulates M1/M2 Macrophage Polarization to Relieve CLP-Induced Inflammation via TLR4-Mediated NF-кb and MAPK Pathways. J Inflamm Res 2021;14:2045-60. 10.2147/JIR.S307801</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/JIR.S307801</ArticleId><ArticleId IdType="pmc">PMC8144186</ArticleId><ArticleId IdType="pubmed">34045880</ArticleId></ArticleIdList></Reference><Reference><Citation>Okeke EB, Louttit C, Fry C, et al. Inhibition of neutrophil elastase prevents neutrophil extracellular trap formation and rescues mice from endotoxic shock. Biomaterials 2020;238:119836. 10.1016/j.biomaterials.2020.119836</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biomaterials.2020.119836</ArticleId><ArticleId IdType="pmc">PMC7075277</ArticleId><ArticleId IdType="pubmed">32045782</ArticleId></ArticleIdList></Reference><Reference><Citation>Aikawa N, Kawasaki Y. Clinical utility of the neutrophil elastase inhibitor sivelestat for the treatment of acute respiratory distress syndrome. Ther Clin Risk Manag 2014;10:621-9. 10.2147/TCRM.S65066</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/TCRM.S65066</ArticleId><ArticleId IdType="pmc">PMC4130327</ArticleId><ArticleId IdType="pubmed">25120368</ArticleId></ArticleIdList></Reference><Reference><Citation>Chinese Research Hospital Association of Critical Care Medicine, China Medical Education Association of Critical Care Medicine . Chinese experts’ consensus on clinical application of Sivelestat Sodium. Chinese Journal of Hygiene Rescue (Electronic Edition) 2022;08:1-5.</Citation></Reference><Reference><Citation>Fujimura N, Obara H, Suda K, et al. Neutrophil elastase inhibitor improves survival rate after ischemia reperfusion injury caused by supravisceral aortic clamping in rats. J Surg Res 2013;180:e31-6. 10.1016/j.jss.2012.04.037</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jss.2012.04.037</ArticleId><ArticleId IdType="pubmed">22595015</ArticleId></ArticleIdList></Reference><Reference><Citation>Tao W, Miao QB, Zhu YB, et al. Inhaled neutrophil elastase inhibitor reduces oleic acid-induced acute lung injury in rats. Pulm Pharmacol Ther 2012;25:99-103. 10.1016/j.pupt.2011.12.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pupt.2011.12.006</ArticleId><ArticleId IdType="pubmed">22210005</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayashida K, Fujishima S, Sasao K, et al. Early administration of sivelestat, the neutrophil elastase inhibitor, in adults for acute lung injury following gastric aspiration. Shock 2011;36:223-7. 10.1097/SHK.0b013e318225acc3</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SHK.0b013e318225acc3</ArticleId><ArticleId IdType="pubmed">21617577</ArticleId></ArticleIdList></Reference><Reference><Citation>Chai JK, Cai JH, Deng HP, et al. Role of neutrophil elastase in lung injury induced by burn-blast combined injury in rats. Burns 2013;39:745-53. 10.1016/j.burns.2012.08.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.burns.2012.08.005</ArticleId><ArticleId IdType="pubmed">22999209</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao J, Liu Q. Protective effects of sivelestat in a caerulein-induced rat acute pancreatitis model. Inflammation 2013;36:1348-56. 10.1007/s10753-013-9674-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10753-013-9674-3</ArticleId><ArticleId IdType="pubmed">23794035</ArticleId></ArticleIdList></Reference><Reference><Citation>Colakerol A, Suzan S, Temiz MZ, et al. Tissue neutrophil elastase contributes to extracorporeal shock wave lithotripsy-induced kidney damage and the neutrophil elastase inhibitor, sivelestat, attenuates kidney damage with gratifying immunohistopathological and biochemical findings: an experimental study. Urolithiasis 2022;50:103-12. 10.1007/s00240-021-01287-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00240-021-01287-x</ArticleId><ArticleId IdType="pubmed">34778918</ArticleId></ArticleIdList></Reference><Reference><Citation>Lessieur EM, Liu H, Saadane A, et al. Neutrophil-Derived Proteases Contribute to the Pathogenesis of Early Diabetic Retinopathy. Invest Ophthalmol Vis Sci 2021;62:7. 10.1167/iovs.62.13.7</Citation><ArticleIdList><ArticleId IdType="doi">10.1167/iovs.62.13.7</ArticleId><ArticleId IdType="pmc">PMC8525836</ArticleId><ArticleId IdType="pubmed">34643662</ArticleId></ArticleIdList></Reference><Reference><Citation>Niu X, Liu F, Li W, et al. Cavidine Ameliorates Lipopolysaccharide-Induced Acute Lung Injury via NF-κB Signaling Pathway in vivo and in vitro. Inflammation 2017;40:1111-22. 10.1007/s10753-017-0553-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10753-017-0553-1</ArticleId><ArticleId IdType="pubmed">28365871</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukatsu M, Ohkawara H, Wang X, et al. The suppressive effects of Mer inhibition on inflammatory responses in the pathogenesis of LPS-induced ALI/ARDS. Sci Signal 2022;15:eabd2533. 10.1126/scisignal.abd2533</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scisignal.abd2533</ArticleId><ArticleId IdType="pubmed">35258998</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang R, Xu J, Zhang Y, et al. Ligustrazine Alleviate Acute Lung Injury Through Suppressing Pyroptosis and Apoptosis of Alveolar Macrophages. Front Pharmacol 2021;12:680512. 10.3389/fphar.2021.680512</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2021.680512</ArticleId><ArticleId IdType="pmc">PMC8193053</ArticleId><ArticleId IdType="pubmed">34122107</ArticleId></ArticleIdList></Reference><Reference><Citation>Ji W, Zhang X, Sang C, et al. Punicalin attenuates LPS-induced acute lung injury by inhibiting inflammatory cytokine production and MAPK/NF-κB signaling in mice. Heliyon 2023;9:e15434. 10.1016/j.heliyon.2023.e15434</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.heliyon.2023.e15434</ArticleId><ArticleId IdType="pmc">PMC10123264</ArticleId><ArticleId IdType="pubmed">37101633</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu L, Zhou X, Shetty S, et al. HDAC6 inhibition blocks inflammatory signaling and caspase-1 activation in LPS-induced acute lung injury. Toxicol Appl Pharmacol 2019;370:178-83. 10.1016/j.taap.2019.03.017</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.taap.2019.03.017</ArticleId><ArticleId IdType="pubmed">30910594</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu F, Wang S, Wang Y, et al. Inhibition of gp130 alleviates LPS-induced lung injury by attenuating apoptosis and inflammation through JAK1/STAT3 signaling pathway. Inflamm Res 2023;72:493-507. 10.1007/s00011-022-01686-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00011-022-01686-9</ArticleId><ArticleId IdType="pubmed">36617342</ArticleId></ArticleIdList></Reference><Reference><Citation>Terzi F, Demirci B, Çınar İ, et al. Effects of tocilizumab and dexamethasone on the downregulation of proinflammatory cytokines and upregulation of antioxidants in the lungs in oleic acid-induced ARDS. Respir Res 2022;23:249. 10.1186/s12931-022-02172-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12931-022-02172-w</ArticleId><ArticleId IdType="pmc">PMC9482261</ArticleId><ArticleId IdType="pubmed">36115998</ArticleId></ArticleIdList></Reference><Reference><Citation>Sinha S, Cheng K, Schäffer AA, et al. In vitro and in vivo identification of clinically approved drugs that modify ACE2 expression. Mol Syst Biol 2020;16:e9628. 10.15252/msb.20209628</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/msb.20209628</ArticleId><ArticleId IdType="pmc">PMC7390914</ArticleId><ArticleId IdType="pubmed">32729248</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan Q, Jiang YW, Fang QH. Improving effect of Sivelestat on lipopolysaccharide-induced lung injury in rats. APMIS 2014;122:810-7. 10.1111/apm.12222</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/apm.12222</ArticleId><ArticleId IdType="pubmed">24484066</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang F, Yang J, Zhang Y, et al. Angiotensin-converting enzyme 2 and angiotensin 1-7: novel therapeutic targets. Nat Rev Cardiol 2014;11:413-26. 10.1038/nrcardio.2014.59</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrcardio.2014.59</ArticleId><ArticleId IdType="pmc">PMC7097196</ArticleId><ArticleId IdType="pubmed">24776703</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu J, Yang J, Chen J, et al. Vitamin D alleviates lipopolysaccharide-induced acute lung injury via regulation of the renin-angiotensin system. Mol Med Rep 2017;16:7432-8. 10.3892/mmr.2017.7546</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/mmr.2017.7546</ArticleId><ArticleId IdType="pmc">PMC5865875</ArticleId><ArticleId IdType="pubmed">28944831</ArticleId></ArticleIdList></Reference><Reference><Citation>Shenoy V, Ferreira AJ, Qi Y, et al. The angiotensin-converting enzyme 2/angiogenesis-(1-7)/Mas axis confers cardiopulmonary protection against lung fibrosis and pulmonary hypertension. Am J Respir Crit Care Med 2010;182:1065-72. 10.1164/rccm.200912-1840OC</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/rccm.200912-1840OC</ArticleId><ArticleId IdType="pmc">PMC2970847</ArticleId><ArticleId IdType="pubmed">20581171</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L, Wang Y, Yang T, et al. Angiotensin-Converting Enzyme 2 Attenuates Bleomycin-Induced Lung Fibrosis in Mice. Cell Physiol Biochem 2015;36:697-711. 10.1159/000430131</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000430131</ArticleId><ArticleId IdType="pubmed">25998889</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen QF, Kuang XD, Yuan QF, et al. Lipoxin A(4) attenuates LPS-induced acute lung injury via activation of the ACE2-Ang-(1-7)-Mas axis. Innate Immun 2018;24:285-96. 10.1177/1753425918785008</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1753425918785008</ArticleId><ArticleId IdType="pmc">PMC6830918</ArticleId><ArticleId IdType="pubmed">29969931</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, Cao Y, Zeng Z, et al. Angiotensin-converting enzyme 2/angiotensin-(1-7)/Mas axis prevents lipopolysaccharide-induced apoptosis of pulmonary microvascular endothelial cells by inhibiting JNK/NF-κB pathways. Sci Rep 2015;5:8209. 10.1038/srep08209</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep08209</ArticleId><ArticleId IdType="pmc">PMC4314638</ArticleId><ArticleId IdType="pubmed">25644821</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan R, Li Y, Han S, et al. Fe-Curcumin Nanozyme-Mediated Reactive Oxygen Species Scavenging and Anti-Inflammation for Acute Lung Injury. ACS Cent Sci 2022;8:10-21. 10.1021/acscentsci.1c00866</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acscentsci.1c00866</ArticleId><ArticleId IdType="pmc">PMC8796308</ArticleId><ArticleId IdType="pubmed">35106369</ArticleId></ArticleIdList></Reference><Reference><Citation>Maloney JP, Gao L. Proinflammatory Cytokines Increase Vascular Endothelial Growth Factor Expression in Alveolar Epithelial Cells. Mediators Inflamm 2015;2015:387842. 10.1155/2015/387842</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2015/387842</ArticleId><ArticleId IdType="pmc">PMC4573992</ArticleId><ArticleId IdType="pubmed">26424968</ArticleId></ArticleIdList></Reference><Reference><Citation>Lv X, Yao T, He R, et al. Protective Effect of Fluorofenidone Against Acute Lung Injury Through Suppressing the MAPK/NF-κB Pathway. Front Pharmacol 2021;12:772031. 10.3389/fphar.2021.772031</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2021.772031</ArticleId><ArticleId IdType="pmc">PMC8721041</ArticleId><ArticleId IdType="pubmed">34987397</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan Z, Gibson SA, Buckley JA, et al. Role of the JAK/STAT signaling pathway in regulation of innate immunity in neuroinflammatory diseases. Clin Immunol 2018;189:4-13. 10.1016/j.clim.2016.09.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clim.2016.09.014</ArticleId><ArticleId IdType="pmc">PMC5573639</ArticleId><ArticleId IdType="pubmed">27713030</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun X, Cheng H, Liu B, et al. Icariin reduces LPS-induced acute lung injury in mice undergoing bilateral adrenalectomy by regulating GRα. Eur J Pharmacol 2020;876:173032. 10.1016/j.ejphar.2020.173032</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejphar.2020.173032</ArticleId><ArticleId IdType="pubmed">32147435</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen L, Liu HG, Liu W, et al. Analysis of clinical features of 29 patients with 2019 novel coronavirus pneumonia. Zhonghua Jie He He Hu Xi Za Zhi 2020;43:203-8. 10.3760/cma.j.issn.1001-0939.2020.03.013</Citation><ArticleIdList><ArticleId IdType="doi">10.3760/cma.j.issn.1001-0939.2020.03.013</ArticleId><ArticleId IdType="pubmed">32164089</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao F, Tian X, Li Z, et al. Suppression of NLRP3 Inflammasome by Erythropoietin via the EPOR/JAK2/STAT3 Pathway Contributes to Attenuation of Acute Lung Injury in Mice. Front Pharmacol 2020;11:306. 10.3389/fphar.2020.00306</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2020.00306</ArticleId><ArticleId IdType="pmc">PMC7096553</ArticleId><ArticleId IdType="pubmed">32265704</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JM, Yeo CD, Lee HY, et al. Inhibition of neutrophil elastase contributes to attenuation of lipopolysaccharide-induced acute lung injury during neutropenia recovery in mice. J Anesth 2017;31:397-404. 10.1007/s00540-017-2311-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00540-017-2311-9</ArticleId><ArticleId IdType="pubmed">28144780</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>